INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 1,509 Million by 2030 | 3.3 % | North America |
| by Type | by Application |
|---|---|
|
|
SCOPE OF THE REPORT
Heparin (Heparin Sodium and Heparin Calcium) Market Overview
The global Heparin (Heparin Sodium and Heparin Calcium) market is anticipated to grow from USD 1,202 Million in 2023 to USD 1,509 Million by 2030, at a CAGR of 3.3 % during the forecast period.
Heparin is an anticoagulant medication that prevents the formation of blood clots. It is commonly used in medical settings to treat and prevent conditions associated with abnormal blood clotting, such as deep vein thrombosis (DVT), pulmonary embolism, and certain cardiovascular procedures. Heparin is primarily used as an anticoagulant to prevent the formation of blood clots. This is crucial in various medical situations where blood clotting can lead to serious complications, such as deep vein thrombosis (DVT), pulmonary embolism, and stroke. Preoperative and Intraoperative Use: Heparin is often administered before surgical procedures to prevent blood clot formation during and after surgery. This is especially important in surgeries involving blood vessels or those at risk of thrombosis.
In medical procedures involving the use of catheters, such as hemodialysis or certain diagnostic tests with contrast agents, Heparin may be used to prevent clotting in the catheter and maintain its patency. Management of Conditions: Heparin is used in the treatment of various conditions related to abnormal blood clotting, including disseminated intravascular coagulation (DIC) and certain cases of venous thromboembolism During hemodialysis, Heparin is used to prevent blood clotting within the dialysis machine, ensuring the efficient and safe removal of waste products from the blood. Prevention of Thromboembolism: Patients with certain cardiovascular conditions, such as atrial fibrillation or heart valve disorders, may be prescribed Heparin to prevent the formation of blood clots that could lead to stroke or other complications.
Heparin may be used in pregnant women at risk of blood clot formation, as it is considered safer than other anticoagulants during pregnancy. In cases of excessive bleeding or emergencies, the anticoagulant effects of Heparin can be partially reversed with the administration of protamine sulfate. Heparin is used in research laboratories and diagnostic settings for various applications, such as studying coagulation pathways and conducting tests that require anticoagulated blood samples.
Cardiovascular diseases, such as deep vein thrombosis (DVT), pulmonary embolism, and heart conditions, are common globally. Heparin is frequently used in the prevention and treatment of conditions associated with abnormal blood clotting, contributing to its market growth. The rising number of surgical procedures, including cardiovascular surgeries and orthopedic procedures, contributes to the increased demand for anticoagulants like Heparin to prevent clot formation during and after surgery. The aging population is more prone to conditions that require anticoagulation therapy. As the global population ages, there is an increased demand for anticoagulants to manage and prevent thrombotic disorders. Increasing awareness among healthcare professionals and the general public about the risks of thrombosis and related conditions may lead to more proactive use of anticoagulants like Heparin for preventive measures.
The use of Heparin in hemodialysis procedures to prevent clotting in dialysis machines contributes to its growing demand, particularly as the number of individuals with kidney diseases increases. Ongoing research and development efforts to improve Heparin formulations, enhance efficacy, and reduce side effects can drive market growth. Awareness about pregnancy-related conditions, such as gestational thrombophilia, where anticoagulation may be required, can contribute to the demand for Heparin. Global health events, such as the COVID-19 pandemic, have underscored the importance of anticoagulation in managing severe cases. Hospital practices during such events may contribute to increased use of anticoagulants. Heparin is used in various research and diagnostic applications in laboratories, contributing to its market growth beyond clinical applications. The expansion of healthcare infrastructure, especially in developing regions, can lead to increased access to healthcare services, including anticoagulation therapy.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2030 |
| Base year | 2022 |
| Estimated year | 2023 |
| Forecasted year | 2023-2030 |
| Historical period | 2019-2021 |
| Unit | Value (USD Million), (Kilotons) |
| Segmentation | By Type, By Application and Region |
| By Type |
|
| Â
By Application |
|
| Â
 By Region  |
|
Heparin (Heparin Sodium and Heparin Calcium) Market Segmentation Analysis
The global Heparin (Heparin Sodium and Heparin Calcium) market is divided into 3 segments type, application and region. by type the market is bifurcated into Heparin Sodium, Heparin Calcium. By application the market is bifurcated into Anticoagulation Therapy, Surgery and Medical Procedures, Hemodialysis, Others.
Based on type Heparin Calcium segment dominating in the Heparin (Heparin Sodium and Heparin Calcium) Market. Heparin Sodium and Heparin Calcium can have similar anticoagulant properties, but they may be preferred in different clinical applications. The choice between the two may depend on factors such as the specific medical condition being treated or the type of medical procedure being performed. Differences in the formulation characteristics of Heparin Sodium and Heparin Calcium, such as bioavailability or pharmacokinetics, might influence their use in specific patient populations or medical scenarios.
Medical practices and preferences can vary across regions and healthcare systems. Certain regions or countries may have a historical preference for one form of heparin over the other. The price and availability of Heparin Sodium and Heparin Calcium can impact their usage. Cost considerations and the availability of one form over the other may influence prescribing decisions. Differences in patient profiles, such as age, medical history, or specific medical conditions, may also play a role in the choice between Heparin Sodium and Heparin Calcium. Ongoing research and development efforts by pharmaceutical companies to improve the formulations, efficacy, and safety profiles of Heparin Calcium could contribute to its dominance in certain markets. Regulatory approvals and guidelines for the use of Heparin Sodium and Heparin Calcium in different regions can impact their market dominance.
Based on application Anticoagulation Therapy segment dominating in the Heparin (Heparin Sodium and Heparin Calcium) Market. Heparin, especially Heparin Sodium, is widely used as an anticoagulant in various medical settings. Anticoagulation therapy is crucial for preventing and treating conditions such as deep vein thrombosis (DVT), pulmonary embolism, and other clotting disorders. Prevalence in Hospitals and Clinics: Anticoagulation therapy is predominantly administered in hospitals and clinical settings, where Heparin is commonly used for immediate and effective anticoagulation in emergency situations.
Heparin is often employed during surgical procedures to prevent clot formation, especially in cardiovascular and orthopedic surgeries. Postoperatively, it may be used to reduce the risk of thromboembolic events. Established Clinical Practices: The use of Heparin in anticoagulation therapy has a long history and is supported by established clinical practices and guidelines. This contributes to the widespread adoption of Heparin in medical institutions.
Anticoagulation therapy with Heparin is crucial in emergency situations, critical care, and intensive care units where rapid and effective anticoagulation is required. Ongoing Research: Continuous research and development efforts in the field of anticoagulation contribute to the expansion of its applications, further solidifying the dominance of Heparin in this therapeutic area. Broad Spectrum of Indications: Heparin is effective in a broad spectrum of indications, making it a versatile choice for anticoagulation in various patient populations and medical conditions. While there are other anticoagulants available, Heparin, with its unique mechanism of action, remains a widely used and preferred choice in many clinical scenarios. Prevalence of Conditions Requiring Anticoagulation: The high incidence of conditions such as atrial fibrillation, venous thromboembolism, and cardiovascular diseases contributes to the continuous demand for anticoagulation therapy Heparin has received regulatory approval for anticoagulation therapy, and its use is often supported by clinical guidelines, further solidifying its position in medical practice. Affordability and Cost-Effectiveness: Heparin is often considered a cost-effective option for anticoagulation therapy, making it accessible in a wide range of healthcare settings.
Heparin (Heparin Sodium and Heparin Calcium) Market Trends
- The demand for anticoagulants, including Heparin, has been on the rise due to the increasing prevalence of cardiovascular diseases, deep vein thrombosis (DVT), and other conditions requiring anticoagulation therapy.
- The global aging population has contributed to the growing incidence of conditions that require anticoagulant treatment. Older individuals are more prone to thrombotic disorders, and as the population ages, the demand for Heparin may continue to increase.
- Ongoing research and development efforts aim to improve the formulations of Heparin, enhancing its efficacy, safety, and patient outcomes. Innovations in drug delivery systems and modifications to reduce side effects are areas of focus.
- Public awareness campaigns and educational initiatives by healthcare organizations have contributed to increased awareness of thrombotic conditions, leading to earlier diagnosis and treatment. This trend supports the demand for anticoagulants like Heparin.
- Heparin is commonly used in hemodialysis procedures to prevent clotting in dialysis machines. As the prevalence of kidney diseases and the need for dialysis services increase, the demand for Heparin in this application may also grow.
- The Heparin market may experience variations in different regions based on factors such as healthcare infrastructure, regulatory landscape, and medical practices. Regional market dynamics can influence trends in Heparin usage.
- The development and introduction of biosimilar versions of Heparin may impact market dynamics. Biosimilars can offer cost-effective alternatives, potentially influencing market trends and competition.
- Pharmaceutical companies and research institutions may engage in collaborations to enhance the development and distribution of Heparin. Partnerships between industry players can drive innovation and market growth.
- Regulatory authorities may intensify scrutiny of anticoagulant medications, including Heparin, to ensure product safety and efficacy. Compliance with evolving regulatory standards can shape market trends.
- Mergers and acquisitions within the pharmaceutical industry can impact the competitive landscape of the Heparin market. Market consolidation may lead to strategic alliances and changes in market share.
Competitive Landscape
The competitive landscape in the Heparin (Heparin Sodium and Heparin Calcium) market  include pharmaceutical companies that produce and distribute Heparin products.
- Pfizer, Inc.
- Sanofi
- Leo Pharma
- Fresenius Kabi
- Aspen Pharmacare
- Shenzhen Hepalink Pharmaceutical Co., Ltd.
- Bioiberica S.A.U.
- Sagent Pharmaceuticals, Inc. (A Nichi-Iko Group Company)
- Syntex S.A.
- Opocrin S.p.A.
- Baxter International Inc.
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
- Dongying Tiandong Pharmaceutical Co., Ltd.
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Pharma Action GmbH
- Yino Pharma Limited
- Nanjing Xinbai Pharmaceutical Co., Ltd.
- Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
- BioXpress Therapeutics SA
- Scientific Protein Laboratories LLC
Recent Developments:
April 21, 2021:Â Fresenius Kabi announced two new presentations of heparin sodium in convenient, ready-to-use Freeflex IV bags in the United States. Fresenius Kabi expanded its critical care portfolio in 2018 by introducing heparin sodium in ready-to-administer non-DEHP Freeflex bags.
Regional Analysis
North america accounted for the largest market in the Heparin (Heparin Sodium and Heparin Calcium) market. North america accounted for the 38 % market share of the global market value. North America has a relatively high prevalence of cardiovascular diseases, including conditions that necessitate anticoagulant therapy. Heparin is commonly prescribed in the region for the prevention and treatment of conditions such as deep vein thrombosis (DVT) and pulmonary embolism. The region is characterized by advanced healthcare infrastructure and medical facilities. The availability of sophisticated medical services and technologies facilitates the diagnosis and treatment of thrombotic disorders, leading to a higher demand for anticoagulants like Heparin.
The aging population in North America contributes to an increased incidence of conditions associated with abnormal blood clotting. Older individuals are more susceptible to thrombotic disorders, and as the population ages, there is a greater demand for anticoagulants. North America, particularly the United States, has one of the highest healthcare expenditures globally. The well-established healthcare system allows for widespread access to medical services and medications, including anticoagulants. The region is a hub for pharmaceutical research and development.
Ongoing efforts to innovate and develop new formulations or delivery methods for Heparin contribute to the market’s growth. There is a high level of awareness and education regarding cardiovascular health and the risks associated with thrombotic conditions. Healthcare professionals and patients are well-informed about the importance of anticoagulation therapy, influencing prescribing practices. Lifestyle factors, such as sedentary lifestyles and dietary habits, contribute to an increased risk of cardiovascular diseases and related conditions. This elevates the need for anticoagulant therapy, further driving the Heparin market.
North America is home to several major pharmaceutical companies that are actively involved in the production and distribution of anticoagulant medications, including Heparin. These companies play a key role in shaping the market landscape. The regulatory environment in North America, particularly the rigorous standards set by health authorities, ensures the safety and efficacy of pharmaceutical products. Compliance with these regulations enhances the confidence of healthcare professionals and patients in using Heparin. The frequency of hospital admissions and surgical procedures in North America contributes to the demand for anticoagulants. Heparin is commonly used in perioperative settings to prevent clot formation during and after surgeries.
Target Audience for Heparin (Heparin Sodium and Heparin Calcium) Market
- Physicians
- Cardiologists
- Surgeons
- Nephrologists
- Pharmaceutical Manufacturers
- Research and Development Teams
- Patients with Cardiovascular Diseases
- Hospital Administrators
- Pharmacy Managers
- Health Regulatory Agencies
- Drug Approval Bodies
- Integrated Health Systems
- Pharmaceutical Distributors
- Clinical Research Institutions
- Government Health Departments
- Patient Advocacy Groups
- Healthcare Insurance Companies
Segments Covered in the Heparin (Heparin Sodium and Heparin Calcium) Market Report
Heparin (Heparin Sodium and Heparin Calcium) Market by Type 2020-2030, USD Million, (Kilotons)
- Heparin Sodium
- Heparin Calcium
Heparin (Heparin Sodium and Heparin Calcium) Market by Application 2020-2030, USD Million, (Kilotons)
- Anticoagulation Therapy
- Surgery and Medical Procedures
- Â Hemodialysis
- Others
Heparin (Heparin Sodium and Heparin Calcium) Market by Region 2020-2030, USD Million, (Kilotons)
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Key Question Answered
- What is the expected growth rate of the heparin (heparin sodium and heparin calcium) market over the next 7 years?
- Who are the major players in the heparin (heparin sodium and heparin calcium) market and what is their market share?
- What are the end-user industries driving market demand and what is their outlook?
- What are the opportunities for growth in emerging markets such as aria-pacific, the middle east, and africa?
- How is the economic environment affecting the heparin (heparin sodium and heparin calcium) market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the heparin (heparin sodium and heparin calcium) market?
- What is the current and forecasted size and growth rate of the global heparin (heparin sodium and heparin calcium) market?
- What are the key drivers of growth in the heparin (heparin sodium and heparin calcium) market?
- Who are the major players in the market and what is their market share?
- What are the distribution channels and supply chain dynamics in the heparin (heparin sodium and heparin calcium) market?
- What are the technological advancements and innovations in the heparin (heparin sodium and heparin calcium) market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the heparin (heparin sodium and heparin calcium) market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the heparin (heparin sodium and heparin calcium) market?
- What are the product offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA TYPES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET OUTLOOK
- GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE, 2020-2030, (USD MILLION), (KILOTONS)
- HEPARIN SODIUM
- HEPARIN CALCIUM
- GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION, 2020-2030, (USD MILLION), (KILOTONS)
- ANTICOAGULATION THERAPY
- SURGERY AND MEDICAL PROCEDURES
- HEMODIALYSIS
- OTHERS
- GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY REGION, 2020-2030, (USD MILLION), (KILOTONS)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES*
(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)
- PFIZER, INC.
- SANOFI
- LEO PHARMA
- FRESENIUS KABI
- ASPEN PHARMACARE
- SHENZHEN HEPALINK PHARMACEUTICAL CO., LTD.
- BIOIBERICA S.A.U.
- SAGENT PHARMACEUTICALS, INC. (A NICHI-IKO GROUP COMPANY)
- SYNTEX S.A.
- OPOCRIN S.P.A.
- BAXTER INTERNATIONAL INC.
- NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO., LTD.
- DONGYING TIANDONG PHARMACEUTICAL CO., LTD.
- CHANGZHOU QIANHONG BIO-PHARMA CO., LTD.
- PHARMA ACTION GMBH
- YINO PHARMA LIMITED
- NANJING XINBAI PHARMACEUTICAL CO., LTD.
- HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.
- BIOXPRESS THERAPEUTICS SA
- SCIENTIFIC PROTEIN LABORATORIES LLCÂ Â *THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 2 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 3 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 4 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 5 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY REGION (USD MILLION) 2020-2030
TABLE 6 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY REGION (KILOTONS) 2020-2030
TABLE 7 NORTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (USD MILLION) 2020-2030
TABLE 8 NORTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (KILOTONS) 2020-2030
TABLE 9 NORTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 10 NORTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 11 NORTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 12 NORTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 13 US HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 14 US HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 15 US HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 16 US HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 17 CANADA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 18 CANADA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 19 CANADA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 20 CANADA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 21 MEXICO HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 22 MEXICO HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 23 MEXICO HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 24 MEXICO HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 25 SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (USD MILLION) 2020-2030
TABLE 26 SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (KILOTONS) 2020-2030
TABLE 27 SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 28 SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 29 SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 30 SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 31 BRAZIL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 32 BRAZIL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 33 BRAZIL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 34 BRAZIL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 35 ARGENTINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 36 ARGENTINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 37 ARGENTINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 38 ARGENTINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 39 COLOMBIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 40 COLOMBIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 41 COLOMBIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 42 COLOMBIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 43 REST OF SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 44 REST OF SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 45 REST OF SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 46 REST OF SOUTH AMERICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 47 ASIA-PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (USD MILLION) 2020-2030
TABLE 48 ASIA-PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (KILOTONS) 2020-2030
TABLE 49 ASIA-PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 50 ASIA-PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 51 ASIA-PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 52 ASIA-PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 53 INDIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 54 INDIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 55 INDIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 56 INDIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 57 CHINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 58 CHINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 59 CHINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 60 CHINA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 61 JAPAN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 62 JAPAN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 63 JAPAN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 64 JAPAN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 65 SOUTH KOREA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 66 SOUTH KOREA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 67 SOUTH KOREA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 68 SOUTH KOREA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 69 AUSTRALIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 70 AUSTRALIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 71 AUSTRALIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 72 AUSTRALIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 73 SOUTH-EAST ASIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 74 SOUTH-EAST ASIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 75 SOUTH-EAST ASIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 76 SOUTH-EAST ASIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 77 REST OF ASIA PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 78 REST OF ASIA PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 79 REST OF ASIA PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 80 REST OF ASIA PACIFIC HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 81 EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (USD MILLION) 2020-2030
TABLE 82 EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (KILOTONS) 2020-2030
TABLE 83 EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 84 EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 85 EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 86 EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 87 GERMANY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 88 GERMANY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 89 GERMANY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 90 GERMANY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 91 UK HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 92 UK HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 93 UK HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 94 UK HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 95 FRANCE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 96 FRANCE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 97 FRANCE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 98 FRANCE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 99 ITALY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 100 ITALY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 101 ITALY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 102 ITALY HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 103 SPAIN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 104 SPAIN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 105 SPAIN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 106 SPAIN HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 107 RUSSIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 108 RUSSIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 109 RUSSIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 110 RUSSIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 111 REST OF EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 112 REST OF EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 113 REST OF EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 114 REST OF EUROPE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 115 MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (USD MILLION) 2020-2030
TABLE 116 MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY COUNTRY (KILOTONS) 2020-2030
TABLE 117 MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 118 MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 119 MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 120 MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 121 UAE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 122 UAE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 123 UAE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 124 UAE HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 125 SAUDI ARABIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 126 SAUDI ARABIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 127 SAUDI ARABIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 128 SAUDI ARABIA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 129 SOUTH AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 130 SOUTH AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 131 SOUTH AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 132 SOUTH AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
TABLE 133 REST OF MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
TABLE 134 REST OF MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (KILOTONS) 2020-2030
TABLE 135 REST OF MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
TABLE 136 REST OF MIDDLE EAST AND AFRICA HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (KILOTONS) 2020-2030
LIST OF FIGURES
FIGURE 1 MARKET DYNAMICS
FIGURE 2 MARKET SEGMENTATION
FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4 DATA TRIANGULATION
FIGURE 5 BOTTOM-UP APPROACH
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 RESEARCH FLOW
FIGURE 8 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2020-2030
FIGURE 9 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2020-2030
FIGURE 13 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY REGION (USD MILLION) 2020-2030
FIGURE 14 PORTER’S FIVE FORCES MODEL
FIGURE 15 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY TYPE (USD MILLION) 2022
FIGURE 16 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY APPLICATION (USD MILLION) 2022
FIGURE 17 GLOBAL HEPARIN (HEPARIN SODIUM AND HEPARIN CALCIUM) MARKET BY REGION (USD MILLION) 2022
FIGURE 18 MARKET SHARE ANALYSIS
FIGURE 19 PFIZER, INC: COMPANY SNAPSHOT
FIGURE 20 SANOFI: COMPANY SNAPSHOT
FIGURE 21 LEO PHARMA: COMPANY SNAPSHOT
FIGURE 22 FRESENIUS KABI: COMPANY SNAPSHOT
FIGURE 23 ASPEN PHARMACARE: COMPANY SNAPSHOT
FIGURE 24 SHENZHEN HEPALINK PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
FIGURE 25 BIOIBERICA S.A.U.: COMPANY SNAPSHOT
FIGURE 26 SAGENT PHARMACEUTICALS, INC. (A NICHI-IKO GROUP COMPANY): COMPANY SNAPSHOT
FIGURE 27 SYNTEX S.A.: COMPANY SNAPSHOT
FIGURE 28 OPOCRIN S.P.A. COMPANY SNAPSHOT
FIGURE 29 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
FIGURE 30 NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
FIGURE 31 DONGYING TIANDONG PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
FIGURE 32 CHANGZHOU QIANHONG BIO-PHARMA CO., LTD.: COMPANY SNAPSHOT
FIGURE 33 PHARMA ACTION GMBH: COMPANY SNAPSHOT
FIGURE 34 NANJING XINBAI PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
FAQ
The global Heparin (Heparin Sodium and Heparin Calcium) market is anticipated to grow from USD 1,202 Million in 2023 to USD 1,509 Million by 2030, at a CAGR of 3.3 % during the forecast period.
North america accounted for the largest market in the Heparin (Heparin Sodium and Heparin Calcium) market. North america accounted for 38 % market share of the global market value.
Pfizer, Inc., Sanofi, Leo Pharma, Fresenius Kabi, Aspen Pharmacare, Shenzhen Hepalink Pharmaceutical Co., Ltd., Bioiberica S.A.U., Sagent Pharmaceuticals, Inc. (A Nichi-Iko Group Company), Syntex S.A.
The demand for anticoagulants, including Heparin, has been on the rise due to the increasing prevalence of cardiovascular diseases, deep vein thrombosis (DVT), and other conditions requiring anticoagulation therapy. The global aging population has contributed to the growing incidence of conditions that require anticoagulant treatment. Older individuals are more prone to thrombotic disorders, and as the population ages, the demand for Heparin may continue to increase.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.